![BS 499 Part 1 [1965]](https://static.fdocuments.nl/doc/165x107/54081862dab5cac8598b460a/bs-499-part-1-1965.jpg)
Octreotide
1
Octreotide Hypoglycaemia: 3 case reports Three patients with acromegaly received SC octreotide 100 tid . After 1 month 's therapy patients were evaluated for the effectiveness of treatment. Sudden symptoms of hypoglycaemia developed in 2 patients and all 3 were shown to have depressed serum glucose levels, despite a controlled diet. It was demonstrated that insu lin levels were depressed 1 hour after octreotide administration , with gradual resolution . The authors concluded that " , , one has to bear in mind the possibility of hypoglycaemia, when treating acromegalic patients with Sandostatin [octreotlde ]' , POPOVIC V. Nesovlc M, Kendereskl A. Zarkovlc M. 0JordJevlc p. et al Hypoglycaemla In acromegalic patients treated with long acllng somatostatin analogue (SMS 201 ·995) Hormone and Melabolic Research 21 282·284 . May 1989 ,.. Induction of severe hypoglycaemia in patients with pancreatic insulinomas: 2 case reports Long·acting somatostatin analogues have been used in patients with insulinomas to control insulin·induced hypoglycaemia. A 77 ·year·old woman (patient 1) and a 50-year·old man (patient 2) experienced severe hypoglycaemic episodes which required hospitalisat ion. Both patients were diagnosed with pancreatic insulinoma. The ability of octreotide to control insulin-induced hypoglycaemia was assessed in these patients. Prior to breakfast, both patients received SC octreotide ('Sandostatin ') severe hypoglycaemia occurred in both patients. The ne xt day, patient 2 received an additional dose of octreotide after breakfast with no hypoglycaemia observed . Following octreotide studies a 3 x 3 x 2cm tumour was found and removed from the tail of the pancreas in patient 1 and a 1 cm diameter tumour was removed from the head of the pancreas in patient 2. Metastases were observed in patient 1 and she was treated with streptolocin, with complete remission. Postsurgery, glucose and insulin levels returned to normal in patient 2. Thus, " , , in patients with an insulin- secreting tumour, treatment with the long-acting somatostatin analogue octreotide may be associated with a transient decrease in serum glucose levels, This may result in clinically important hypoglycemia ', Slehouwer COA, Lems WF , Fischer HRA. Hackeng WHL. Naafs MAS. Aggravation of hypoglycemia in insulinoma palients by the long· acting somatostatin analogue octreotide (San dostatin@) . Acta Endocrinologica 121 : 34·40 . Jull989 ...
Transcript of Octreotide
Octreotide Hypoglycaemia: 3 case reports
Three patients with acromegaly received SC octreotide 100 ~g tid . After 1 month 's therapy patients were evaluated for the effectiveness of treatment.
Sudden symptoms of hypoglycaemia developed in 2 patients and all 3 were shown to have depressed serum glucose levels, despite a controlled diet. It was demonstrated that insulin levels were depressed 1 hour after octreotide administration , with gradual resolution .
The authors concluded that " , , one has to bear in mind the possibility of hypoglycaemia, when treating acromegalic patients with Sandostatin [octreotlde ]',
POPOVIC V. Nesovlc M, Kendereskl A. Zarkovlc M. 0JordJevlc p. et al Hypoglycaemla In acromegalic patients treated with long acllng somatostatin analogue (SMS 201 ·995) Hormone and Melabolic Research 21 282·284 . May 1989 ,..
Induction of severe hypoglycaemia in patients with pancreatic insulinomas: 2 case reports
Long·acting somatostatin analogues have been used in patients with insulinomas to control insulin·induced hypoglycaemia. A 77·year·old woman (patient 1) and a 50-year·old man (patient 2) experienced severe hypoglycaemic episodes which required hospitalisation. Both patients were diagnosed with pancreatic insulinoma.
The ability of octreotide to control insulin-induced hypoglycaemia was assessed in these patients. Prior to breakfast , both patients received SC octreotide ('Sandostatin ') 50~g ; severe hypoglycaemia occurred in both patients . The next day, patient 2 received an additional dose of octreotide after breakfast with no hypoglycaemia observed .
Following octreotide studies a 3 x 3 x 2cm tumour was found and removed from the tail of the pancreas in patient 1 and a 1 cm diameter tumour was removed from the head of the pancreas in patient 2. Metastases were observed in patient 1 and she was treated with streptolocin , with complete remission. Postsurgery, glucose and insulin levels returned to normal in patient 2.
Thus, " , , in patients with an insulinsecreting tumour, treatment with the long-acting somatostatin analogue octreotide may be associated with a transient decrease in serum glucose levels, This may result in clinically important hypoglycemia ',
Slehouwer COA, Lems WF , Fischer HRA. Hackeng WHL. Naafs MAS. Aggravation of hypoglycemia in insulinoma palients by the long· acting somatostatin analogue octreotide (Sandostatin@). Acta Endocrinologica 121 : 34·40. Jull989 ...
